SCHEMBL24744902

SCHEMBL24744902

COC(=O)c1c(F)ccc2[nH]c(C)nc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
NR4A2 P43354 2/20 0.40
KMT2A Q03164 2/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.39
DHODH Q02127 3/20 0.38
ADRB2 P07550 1/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HRH4 Q9H3N8 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TLR8 Q9NR97 1/20 0.37
PKN1 Q16512 1/20 0.36
PKN2 Q16513 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8953009 0.84 PARP1 (0.47) PARP1ABCG2NR4A2KMT2AALDH1A1
SCHEMBL13544493 0.83 PARP1 (0.45) PARP1DHODHADRB2HRH4
SCHEMBL13544691 0.83 PARP1 (0.45) PARP1DHODHADRB2HTTHRH4
SCHEMBL1080091 0.82 PARP1 (0.42) PARP1ABCG2NR4A2KMT2AALDH1A1
SCHEMBL15808372 0.77 HPGD (0.42) PARP1KMT2AALDH1A1POLBLMNA
SCHEMBL24745135 0.76 MPO (0.39) PARP1ABCG2KMT2APOLBLMNA
SCHEMBL30000629 0.76 MPO (0.39) PARP1ABCG2KMT2APOLBLMNA
SCHEMBL6946608 0.76 CREBBP (0.50) GAA
SCHEMBL1081543 0.75 LMNA (0.39) PARP1NR4A2KMT2AALDH1A1POLB
SCHEMBL7421982 0.75 PARP1 (0.47) PARP1NR4A2KMT2ALMNADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP PARP1 429/4885ABCG2 797/4885NR4A2 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.